revealed that subcutaneous administration of human Wharton’s jelly-derived MSCs (WJ-MSCs) preconditioned with the Toll-like receptor 3 agonist poly I:C or IFN-γ can decrease the levels of proinflammatory cytokines in a murine model of AD. The gene discussed is IFNG; the disease is Alzheimer disease.